As drug development pushes into more complex antibody formats, the big question is: how do you really assess developability? In this episode, host Nimish Gera speaks with Shamit Shrivastava, Ph.D., founder and CEO of Apoha, to dive into Liquid Brain, his interdisciplinary innovation that’s changing the way researchers tackle developability of challenging antibody-based drugs. Shamit breaks down what makes Liquid Brain different from traditional developability methods, reveals how it’s unlocki...
All content for The Chain: Protein Engineering Podcast is the property of Cambridge Healthtech Institute and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
As drug development pushes into more complex antibody formats, the big question is: how do you really assess developability? In this episode, host Nimish Gera speaks with Shamit Shrivastava, Ph.D., founder and CEO of Apoha, to dive into Liquid Brain, his interdisciplinary innovation that’s changing the way researchers tackle developability of challenging antibody-based drugs. Shamit breaks down what makes Liquid Brain different from traditional developability methods, reveals how it’s unlocki...
Episode 65- Tariq Ghayur on the Renaissance of Bispecifics and ADCs, AI, and More
The Chain: Protein Engineering Podcast
31 minutes
1 year ago
Episode 65- Tariq Ghayur on the Renaissance of Bispecifics and ADCs, AI, and More
September 10, 2024 | In this episode of The Chain, host Nimish Gera speaks with Tariq Ghayur, founder of FairJourney Biologics (and a fellow host of the podcast), about the current renaissance of bispecifics and ADCs, the impact of AI in pharmaceuticals, and what to watch out for in the biopharma space in the next few years. Ghayur also shares his journey from BASF Pharma to AbbVie, what it was like when the industry shifted its focus from small molecules to biologics, and the major differenc...
The Chain: Protein Engineering Podcast
As drug development pushes into more complex antibody formats, the big question is: how do you really assess developability? In this episode, host Nimish Gera speaks with Shamit Shrivastava, Ph.D., founder and CEO of Apoha, to dive into Liquid Brain, his interdisciplinary innovation that’s changing the way researchers tackle developability of challenging antibody-based drugs. Shamit breaks down what makes Liquid Brain different from traditional developability methods, reveals how it’s unlocki...
